CSI Market
Sign In | Register

Aim Immunotech Inc (AIM) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AIM quarterly Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Aim Immunotech Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-13.96
Depreciation & amortization0.04
Amortization of Other Assets0.73
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived1.14
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.06
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.27
Standby Finance Finance Costs-
Derivative Gain On Derivative-
Amortization And Abandonment Of Intagible Assets-
Other Than Temporary Impairment Losses Investments Availableforsale Securities-
Marketable Securities Realized Gain Loss-
Fair Value Of Convertible Note Adjustment-
Change In Convertible Debt Refinancing-
Write Off Of Deferred Debt Issuance Cost-
Increase Decreasein Right of Use Assets-
Fair Value Of Convertible Note Adjustments-
Redeemable Warrants Valuation Adjustment-
Allowance For Loan And Lease Loss Recovery Of Bad Debts-
Warrant Modification-
Abandonment Of Patent And Trademark Rights-
Noncash Lease Expense-
Extinguishment Of Financing Obligation And Note Payables-
Amortization Of Debt Discount And Other Expenses-0.27
Marketable Securities Unrealized Gain Loss-
Income taxes0.00
Gain (Loss) on Sale of Derivatives4.39
Increase (Decrease) in Other Receivables-0.01
Increase (Decrease) in Accounts Payable-1.71
Increase (Decrease) in Accrued Liabilities0.42
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.04
Other Working Capital0.74
Other Noncash Income (Expense)0.29
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.04
Discontinued operations0.00
Net Cash flow from Operating Activities-10.96
Investing Activities
Capital Expenditures-0.38
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities-0.09
Real Estate Investments0.00
Proceeds from Refunded Capital Lease Deposits-
Payments for Office Lease Deposits-
Proceeds from Refund of Capital Lease Deposits-
Office Rental Deposit-
Proceeds From Payments To Acquire Intangible Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net2.32
Discontinued operations0.00
Net Cash Flow from Investing Activities1.85
Financing Activities
Short-term debt Net2.75
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.66
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock7.31
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Margin Account Loan-
Payments On Capital Leases-
Proceeds Payment From Margin Account Loan-
Security Deposit Paid-
Payment Of Financing Obligation-
Proceeds From Issuance Of Equity Warrants-
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Issuance Of Equity Warrants And Prefunded Warrants-
Proceeds From Sale Of Stock Net Of Issuance Costs0.98
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.39
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-11.34
Total Cash Flow1.28
4 historic quarters locked

Sign in to unlock the full Aim Immunotech Inc cash flow history.

Sign In Create Free Account

About Aim Immunotech Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 27, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-013301

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License